反应条件
1: N-tert-butoxycarbonyl-β-alanine With O-<[cyano(ethoxycarbonyl)methylene]amino>-1,1,3,3-tetramethyluronium tetrafluoroborate in DMF (N,N-dimethyl-formamide)
T=20°C; 0.25 h;
2: 2-methyl-quinoline-4,6-diamine With n-ethyl morpholine in DMF (N,N-dimethyl-formamide)
T=20°C; 24 h;
参考文献
Aventis Pharma Deutschland GmbH; AJINOMOTO CO., INC., Pharmaceutical Company
Patent: EP1369420 A1, 2003 ;
Location in patent: Page 12 ;